GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

NCT02673931 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1, given alongside high-oxygen treatment, can help protect organs in adults undergoing heart surgery who have conditions like coronary disease or heart failure.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 1,400 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-02 · est. completion 2024-09

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02673931 ↗

Description as written by the study sponsor.

Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from cardio-pulmonary bypass.

Treatments tested

Byetta (Lilly, Exenatide) also known as GLP-1 agonist Drug

See description of arms
Conoxia (AGA, oxygen) also known as Oxygen Drug

See description arms
20% Human Albumin also known as Albumin Drug

Main thing measured	Time in days to the first occurring of the following co-primary end-points throughout the follow-up period
Sponsor	Rigshospitalet, Denmark
Conditions studied	Coronary Disease, Shock, Cardiogenic, Renal Failure, Stroke, Brain Injury, Aortic Valve Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02673931 ↗